Valve replacement has been one of the most important advances in the management of patients with valvular heart disease. The 10 and 15 year survival rate after isolated aortic and mitral valve replacement with the Starr-Edwards valve is 56 and 44%, respectively. At 5 and 7 years, survival with the Bjork-Shiley, porcine bioprosthesis and the Starr-Edwards valve is similar. Patients operated on during the last 5 to 10 years have a much better survival rate than those operated on in the 1960s; therefore, the 10 and 15 year survival of those operated on recently should improve.
term anticoagulant therapy with drugs of the coumadin type. Porcine bioprostheses have a low failure rate up to 5 years after valve replacement; after this, valve failure occurs at an increasing rate, but the incidence at 10 and 15 years is not known. Valve replacement usually produces a marked improvement in the symptomatic status of the patient because of improved hemodynamics; ventricular function is improved in selected subsets of patients. The role of long-term vasodilator therapy has not been fully determined. Antibiotic prophylaxis for secondary prevention of rheumatic carditis and for prevention of infective endocarditis is important. saved many lives. has enabled a larger number of patients to lead a more active and useful life, and has reached a stage when most patients with valvular heart disease can now be considered potential candidates for surgery. Before we review the results of valve replacement in greater detail, it is useful to briefly consider some problems with data analysis.
Problems With Data Analysis 1. Within the last 10 years presentation of time-related
events has been correctly performed almost uniformly by use ofactuarial techniques. However, it is important to remember that mean survival rates by themselves do not provide adequate information (7) because the precision of the estimated mean is directly affected by the sample size used to determine the mean. The measure of this precision is provided by the standard error of the mean. In general, the use of ± 1 or 2 standard errors of the mean provides an approximate 70 or 95% confidence interval for the true mean; that is, 70 or 95% of the time the true mean will lie within the estimated 1 or 2 standard errors. (23) and at times may give misleading impressions. The population of the United States contains not only normal persons but also persons with malignant tumors, renal and pulmonary failure, operable and inoperable coronary artery disease, emotional disorders and other conditions that put them at high risk of death. The patients chosen for valve replacement are usually highly selected, because they do not have other diseases that are likely to shorten their life. Moreover, patients with valvular heart disease who are not operated on and those who have undergone valve replacement are also included in the overall "normal" population of the United States. 3. When results of any particular procedure are evaluated, the numbers of patients who were excluded from the evaluation should be carefully scrutinized. Mortality and other statistics are influenced by patients who were excluded from the analysis.
Comparison of survival data after valve replacement with survival data from the "normal" United States population is of very limited value

Preoperative information on patients undergoing valve
replacement should be carefully examined. If patients are operated on without undergoing complete preoperative hemodynamic and angiographic studies, then it is possible or even likely that some of them do not have severe valve disease (7, 24) .
Survival curves that exclude hospital mortality may be of value in comparing long-term results of various devices.
However. it is essential to include the hospital mortality statistics to obtain a realistic idea of overall survival.
Comparison of data from different studies can be mis-
leading. Accurate comparison of the results of two studies, whether they are from the same center or from different centers, requires that the patient populations at the start of the studies be identical. Such a situation is unlikely to be obtained except by prospective, well designed, well conducted studios.
Accurate evaluation of prosthesis failure can be difficult.
It cannot be based solely on the number of patients who have been reoperated on, because patients may have prosthesis failure and not come to surgery. Unless almost all patients are examined by the investigators, the diagnosis of prosthesis failure on the basis of the appearance of a "new" murmur may be unreliable. Patients with prosthesis failure may be asymptomatic, and detection of mechanical prosthesis failure by noninvasive methods is not reliable.
It has been learned painfully over the years that one
should be careful about extrapolating data from one device to another, or from one model of a device to another model of the same device. Even subtle changes in design intended to reduce complications may produce new unexpected problems. 9. Similarly, the evaluation of complications of a prosthesis can be difficult. For example, when patients describe certain symptoms. a judgment has to be made as to whether or not these symptoms resulted from systemic emboli. In addition. not all symptoms and bleeding complications are necessarily reported to the physician. 
Valve Replacement
Operative Mortality
Operative mortality is 5% or greater for single and 10% or greater for double valve replacement (1-14,22,25-29). Factors that contribute to operative mortality are heart failure, impaired left ventricular function, functional classes III and IV and associated coronary artery disease. A major cause of operative mortality is the occurrence of perioperative myocardial damage (Table 1) . Better techniques of myocardial protection have resulted in a lesser incidence of myocardial damage and. thus, a reduction in operative mortality (10) .
Perioperative Myocardial Damage
The use of cold cardioplegia with potassium ion arrest and other techniques for better myocardial protection during open heart surgery have led to a significant reduction in perioperative myocardial damage (Table 1 ) (10), the incidence of which is 5% or greater. These improvements have resulted in a lowering of the operative mortality rate; the long-term benefits of adequate myocardial protection should become apparent in the next decade.
Functional Improvement
After successful valve replacement. most patients experience an improvement in functional status because of relief of symptoms (1-14.22.25).
Late Survival
A 20 year follow-up study is available on patients operated on from 1960 to 1980 by Albert Starr (2). The long-term survival rates after isolated aortic and mitral valve replacement were similar; the survival rate at 10 and 15 years was 56 and 44%, respectively (Fig. I) . For double valve replacement the survival rate at 10 and 15 years was 45 and 27%, respectively; and for triple valve replacement the survival rate was 37 and 23%, respectively. The lower survival rate of patients undergoing double and triple valve replacement was the result of increased operative and late mortality. Multivariate analysis showed that the year of operation was the most important determinant of late survival. For isolated valve replacement, there was a significant (p < 0.0 I) increase in survival at 5 years in the current time frame (from 67 to 73%), primarily because of a decrease in operative mortality (Fig. 2 ). In the current time frame, the 5 year survival rate of patients undergoing aortic or mitral valve replacement was 71 and 78%, respectively.
The causes of death are shown in Figure 3 . The cardiacrelated causes of death were heart failure, myocardial infarction, arrhythmia and sudden deaths. The causes of sudden death are listed in Table 2 . The prosthesis-related causes of late death were thromboembolism, ball variance, endocarditis and hemorrhage. The 5 year survival data with the Bjork-Shiley prosthesis (Fig. 4) (3, 25) and the porcine heterograft ( Fig. 5 ) (4-6) and the 10 year survival with the Bjork-Shiley aortic prosthesis (3) are similar to survival data obtained with the Starr-Edwards valve.
Aortic stenosis with clinical heart failure. The 7 year survival rate of this subgroup of patients is 67 ± II % (mean ± standard error of the mean); that of operative survivors is 84 ± 10% (1,9). Because the impaired left ventricular function that is present preoperatively improves markedly after valve replacement, provided there has been no perioperative myocardial damage, variables of left ventricular systolic pump function are not good predictors of late survival in this subset of patients (14) .
Aortic stenosis in patients aged 60 years or more. The 10 and 12 year survival rate of these patients is 56 ± 9% (Fig. 6 ) and that of operative survivors excluding those who died of noncardiac causes is 68±9% (1,14) ; one-third of the late deaths were not of cardiac origin or related to the prosthesis or anticoagulant therapy.
Aortic regurgitation ( Table 3) . The 5 year survival of these patients is best predicted by variables of left ventricular systolic pump function (30) . The 5 year survival rate of patients with a preoperative left ventricular ejection fraction of 0.45 or greater was 87% versus 54% in patients with an ejection fraction of less than 0.45 (p<0.04) (30) ; the rate was 92% in patients with a cardiac index of 2.5 liters per nr' or greater versus 66% in those with an index of less than 2.5 (p<0.04) (11, 30) . Clinically valuable information is obtained from left ventricular ejection fraction and functional class of the patient: patients who had an ejection fraction of 0.50 or greater and were in functional class II to IV or who had an ejection fraction of less than 0.50 but were in functional class I or II had a 5 year survival rate of 90 to 100%; only patients with an ejection fraction of less Mitral valve disease. Patients with predominant mitral regurgitation had a significantly (p<0 .05) lower 5 year survival rate (54%) than that of patients with mitral stenosis or mixed mitral lesions, who se survival rate was 68 and 71%, respectively (27) . In patients with mitral regurgitation, 5 year survival after valve replacement is also determined by the etiology of the mitral regurgitation and by the functional class of the patient. The 5 year survival rate of patients with mitral regurgitation secondary to rheumatic , connective tissue or ischemic heart disease was 57 , 54 and 32% , respectively (Fig . 7) ; the 8 year survival rate of patients in functional classes I, II and III plus IV, was 64,52 and 40 %, respectively (27) .
Late Complications
The major complications that occur after valve replacement are listed in Prosthetic dysfunction. Structural failure of commonly used mechanical prosthe ses is not frequent ; when it occurs. it usuall y involves the strut s of the pro sthe sis. Strut fracture usually does not lead to cata strophic complications; when it is recognized , the patients are able to undergo a second valve replacement. Structural failure is a more common problem with bioprostheses, which undergo degeneration, perforation and calcification , with resulting prosthetic stenosis or regurgitation, or both (Table 5 ). Porcine bioprosthetic failure occurs at a low rate up to 5 years after valve replacement, thereafter occurring at an increasing rate (4,5) (Fig . 8) . The incidence at 10 years is unknown, but data currently available suggest that it may be as low as 15% or as high as 30 to 40 %. Biopro sthetic valve failure cannot be accurately detected by history, physical examination or noninvasive techniques (32).
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.....--~~F igure 3. Causes of late death after single aortic and mitral valve replacement with a caged-ball valve prosthesis. In both time periods the major cause of late death is of cardiac origin. The proportion of deaths due to prosthesis-related causes is smaller in the later time period. but more deaths were due to unknown causes in the second time frame. pt.-yr. = patientyear. (Reprinted from Teply J, Grunkemeier G, Sutherl and HD, et al. [2] , with permission.)
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Total: 100%=4.5%/pt.-yr. The incidence of' 'sudden" prosthetic thrombosis is low except with the Bjork-Shiley valve. The data of Bjork and Henze from Sweden (3) show that the incidence of thrombosed aortic, mitral and tricuspid valve prostheses was 0.3, 1.3 and 2.3 per 100 patient-years, respectively. At 4 years the incidence rate of thrombosed aortic and mitral BjorkShiley prostheses at the University of Alabama (25) was 3 and 13%, respectively ( Table 6 ). The incidence of thrombosed mitral prostheses in both studies was four times greater than that of thrombosed aortic prostheses. The incidence of thrombosed aortic and mitral prostheses was much higher in the data from the University of Alabama than in that from Sweden. The reason for this difference is not known but may relate to the different patient populations, the inclusion in the Swedish series of only patients with a "perfect degree of anticoagulation" or other factors. Bjork and Henze (3) noted a 27-fold increase in the incidence of thrombosed aortic prostheses if anticoagulation was "discontinued or omitted. " The University of Alabama data showed a very high mortality rate (87%) of patients with a thrombosed Bjork-Shiley prosthesis. Perhaps the data from the University of Alabama are more relevant for the usual clinical situation in the United States.
Thromboembolism. Thromboembolism is a major problem associated with use of prosthetic heart valves; the incidence rate is 1 to 2% per year with aortic valve replacement and 2 to 5% per year with mitral valve replacement. The incidence of thromboembolism with mechanical prosthetic valves and porcine bioprostheses has been similar; patients with mechanical valves had received anticoagulant therapy, however. a very small percent of patients with an aortic bioprosthesis received anticoagulant therapy and a significant percent of patients with a mitral bioprosthesis had received anticoagulant therapy. Anticoagulant therapy with drugs of the warfarin type must be used in all patients with a mechanical prosthesis unless there is a specific contraindication to the use of these drugs: anticoagulant therapy must also be used in patients with a porcine heterograft who have a supraventricular arrhythmia such as atrial fibrillation or a very large left atrium.
Hemorrhage. Anticoagulant therapy causes bleeding episodes: major episodes occur in about 1 to 2% of patients per year, death occurs in ::;0.5% of patients per year and minor bleeding episodes occur in about 4 to 8% of patients per year. It is probable that the incidence of bleeding is less in patients in whom adequate anticoagulant therapy can be easily maintained.
Valve prosthesis-patient mismatch. This condition (33, 34) is present when the effective area of the prosthetic valve, after valve insertion into the patient, is less than that of the normal human valve. The reduction in prosthetic valve area is usually mild to moderate in severity and often of no immediate clinical significance. Occasionally, the patient will be hemodynamically and symptomatically worse after valve replacement (33, 34) . The mismatch results mainly from two factors. First, the in vitro effective prosthetic valve area of almost all types of valve replacement devices that can be inserted in patients is less than that of the normal human valve. The in vivo effective prosthetic valve area is even further reduced because of tissue ingrowth and endothelialization; therefore, these devices can be considered "stenotic." Second, the problem is compounded in some patients because the size of the prosthesis that can be inserted is limited by the size of the anulus, which is small compared with the size of the patient, and by the size of the cavity in which the prosthesis must lie. Two issues need emphasis: 1) Valve prosthesis-patient mismatch occurs with all valve replacement devices, and 2) the effective orifice size is only one factor that has to be taken into account when selecting a valve replacement device for an individual patient. Reoperation. This is a serious and a life-threatening complication. It is usually undertaken for prosthetic dysfunction, endocarditis or dehiscence. Occasionally it is undertaken because of repeated thromboemboli and hemorrhage associated with anticoagulant therapy and because of valve prosthesis-patient mismatch.
Choice of Prosthesis
Currently in the United States, two main types of prosthetic heart valves are being implanted-mechanical prostheses and bioprostheses. The two main types of mechanical valves being used are a ball and cage valve (Starr-Edwards valve) and a tilting disc valve (Bjork-Shiley valve). The bioprostheses are porcine heterografts (Hancock and Carpentier-Edwards). After the initial valve replacements in 1960, Starr improved the ball and cage valve, aggressively followed up patients and made a detailed evaluation of the results with sophisticated statistical methods, including use of confidence level. Starr's pioneering work has established the standards by which other prosthetic heart valves are judged: "As is the case for prosthetic mitral valves, the Starr-Edwards caged-ball valve is the 'bench mark' in aortic Figure 5 . Actuarial survival rate of 128 patients with isolated aortic and mitral valve replacement with a porcine heterograft. A small number of patients have been followed up after 6 years. Also. the listed numbers include patients with aortic and with mitral valve replacement. (Reprinted from Cohn LH, Mudge GH. Pratter F. Collins JJ Jr. [6] . with permission.) Mechanical prosthesis versus porcine heterograft. The main advantages of the mechanical prostheses are their proved durability (Starr-Edwards valves up to 15 to 20 years [2] , the Bjork-Shiley valves up to 8 to 10 years in the aortic position and 5 to 7 years in the mitral position [3, 25] ) and the known complications with their rate of occurrence. The greatest advantage of the porcine heterografts is that anticoagulant therapy is not required for patients with sinus rhythm. Because the mechanical valve with anticoagulation and the heterograft valve without anticoagulation have demonstrated similar rates of thromboembolism, the main disadvantage of mechanical valves is the need for anticoagulation and its associated morbidity and mortality. The greatest disadvantage of heterografts is their unknown durability after 10 years.
The choice of a prosthetic heart valve should be made after careful consideration of all factors. Porcine bioprostheses are indicated for patients who cannot take anticoagulant agents, women of child-bearing age who desire pregnancy and patients whose life expectancy from other diseases is likely to be less than 7 years after valve replacement. Mechanical prostheses are indicated for all patients with atrial fibrillation and for patients who require valves in the smaller sizes, patients with "long" life expectancy, and patients who want to reduce the chance of reoperation to a minimum.
Some investigators recommend that bioprostheses be used in all patients aged 60 years and older at the time of valve replacement. Our own data in patients aged 60 years or older with critical aortic stenosis indicate that 50% or more of these patients will be alive 12 years after valve replacement (14) . Because the average age at the time of valve replacement was 68 years, the prospect of reoperating for bioprosthetic failure on 15 to 30% of these survivors 10 years after initial valve replacement at an average age of 78 years does not appear to be very attractive. Thus, the automatic choice of a porcine bioprosthesis for patients aged 60 years and older cannot be justified at present.
Problems with the Bjork-Shiley valve. The previously Also, there is the problem of "sudden" prosthetic thrombosis which appears to have a "high" incidence rate. particularly with valves in the mitral position (3, 25) .
Newer devices. If new prostheses or prostheses with modifications are planned to be used. they must now conform to the law on cardiovascular devices that is regulated by the Federal Food and Dru~Administration (36) . Because we have a choice of several valves with a proved record from 7 to 20 years, the routine clinical use of "newer" devices must be very carefully scrutinized and justified. 
Left Ventricular Function
Aortic valve disease and normal preoperative ventricular function (19) . In patients with aortic stenosis whose left ventricular ejection fraction was normal preoperatively, the ejection fraction remained normal postoperatively (0.71 versus 0.76) provided that there was no significant perioperative myocardiai damage. However, a significant reduction in left ventricular hypertrophy occurred (left ventricular mass was reduced from 229 ± 39 to 133 ± 10 g/rrr', p <0.05), and left ventricular volumes were normal pre-and postoperatively. In patients with aortic regurgitation, left ventricular ejection fraction also showed no significant change (0.64 versus 0.59). Significant reductions in hypertrophy (mass decreased from 222 ± 18 to 128 ± 17 g/m", p <0.025) and in left ventricular size (end-diastolic volume index decreased from 205 ± 22 to 140 ± 24 ml/rrr', p <0.05) occurred. In both groups, abnormalities of left ventricular end-diastolic pressure and cardiac index, if present preoperatively, tended to normalize. Aortic stenosis with impaired left ventricular function and clinical heart failure (9). After successful valve replacement, left ventricular end-diastolic pressure normalizes (reduced from 22 ± 2.4 to 9 ± L 9 mm Hg). If the left ventricular end-diastolic volume was increased preoperatively, then postoperatively there was a significant reduction in end-diastolic volume index from 146 ± 18 to 99 ± 9 ml/rrr' (p <0.025). Left ventricular ejection fraction increased dramatically from 0.34 ± 0.03 to 0.63 ± 0.05 and mean velocity of circumferential fiber shortening also increased' from 0.57 ± 0.08 to 1.03 ± 0.18 circumferences/s (Fig. 10) . The change in ejection fraction needs further mention: 1) Except for the patient who had a perioperative myocardial infarction, all patients experienced an improvement in left ventricular ejection fraction; 2) left ventricular ejection fraction became normal in two-thirds of the patients; and 3) the two patients with the lowest ejection fraction (0.18 and 0.19, respectively) also had dramatic increases in ejection fraction to 0.56 and 0.57.
In general, these patients have an excellent result from valve replacement. These results. however, should not necessarily be expected in patients with heart failure associated with mild (or perhaps moderate) aortic stenosis, because in these patients heart failure would not be expected to be related predominantly to the aortic stenosis. Therefore, the diagnosis of severe aortic stenosis is important. Because the clinical estimation of the severity of aortic stenosis is often in error, particularly in the presence of a low cardiac output, complete hemodynamic evaluation is warranted. For example, four of our patients had a mean aortic gradient of <40 mm Hg (30,30, 33 and 35 mm Hg, respectively) despite the presence of critical aortic stenosis, emphasizing the need for both measuring cardiac output and calculating the aortic valve area. In some patients. it may be preferable to measure these variables both at rest and in a different hemodynamic state, such as that induced by exercise.
Catheterization-proved severe aortic stenosis with or without heart failure, treated nonsurgically . is associated with a 5 year survival rate of 38% and a 10 year survival rate of 10% (37) . A combination of symptoms is an ominous sign (37) . In patients with congestive heart failure, the average life expectancy is less than 2 years (38) . Aortic re gurgitation with im paired left ventricular function (13) . After successful valve replacement, significant reductions in left ventricular end-diastolic pressure (16 ± 3.2 to 10 ± 2 mm Hg), end-diasto lic volume index (209 ± 15 to 155 ± 17 ml/rrr'), end-systolic volume index (118 ± to to 84 ± 14 ml/rrr') and mass (234 ± 11 to 170 ± 16 g/m") occurred (Fig. 11) . In general , len ventricular enddiastolic volume index and mass did not return to normal; however, the patients with the greatest left ventricular enddiastolic volumes and mass had major reductions in both variables . Left ventricular ejection fraction can be expected to increase in approxi mately half of the patients in this subgroup. The mean velocity of circumferential fiber shortening increased from 0.72 ± 0.08 to 0.95 ± 0.11 circumferencesls (p < 0 .05), but became normal in a minority of the patients. It is likely that left ventricular ejection fraction will improve in a higher percentage of patients because of better techniques of myocardial protection that have been used more recently.
Incidence Rate at 4 Years' 
YEARS
Mitral valve disease. In contrast to aortic valve disease. patients with mitral valve disease generally do not experience any significant reduction in left ventricular end-diastolic volume index or ejection fraction (39) (40) (41) (42) . The cardiac index tends to improve and usually there are significant reductions in left atrial pressure (42, 43) .
Studies utilizing M-mode echocardiography (40) indicate that ventricular function tends to decrease slightly postoperatively in patients with mitral regurgitation, even if it was within the normal range preoperatively. although when cardiomegaly is moderate, there is a progressive reduction in ventricular size and mass. Patients with a marked increase in left ventricular size preoperatively on M-mode echocardiography experienced no change in end-diastolic dimension, had a Significant increase in end-systolic dimension and had a significant reduction in the calculated ejection fraction postoperatively. These data suggest that left ventricular function was depressed to a greater degree than was apparent from the calculated ejection fraction because of the low impedance leak from the left ventricle to the left atrium (44) . After the low impedance leak was corrected, the magnitude of depression of ventricular function became manifest because the left ventricle now ejected entirely into the aorta. the serious limitations of M-mode echocardiography in evaluating left ventricular function should be kept in mind.
Other Problems
Coronary Bypass Surgery
The need to perform coronary bypass surgery for associated coronary artery disease in patients undergoing valvular sur- gery has bee n question ed (45) (46) (47) on the basis of 1) lack of difficult y in "success fully" undertaking valve replacement in the presence of coronary artery disease , and 2) absence of differences in surv ival at follow-up of patients with co mbined surgery from that of patients who had not undergone bypass surgery for associated coronary artery disease . These comparisons were made in patients in whom the treatment was not assigned on a random basis. the numbers of patie nts eva luated were very small and the length of followup was very short . Effect on survival. Other data (48 .49) show the patient s who had undergone valve replacement and coronary bypass surgery for associated coronary artery disease had a 10 year survival rate similar to that of patients who had undergone JH. Rahimtoola SH [ 13] . by perm ission of the Ameri can Heart Association, Inc .) valve replacement alone and who did not have coro nary bypass surgery (Fig. 12) . These studies also were not randomized , and the data do not compare patients who did or did not undergo bypass surgery for their associated coronary artery disease. Neverth eless, these data suggest that the deleterious effect of coron ary artery disease on survival was overco me by performing coron ary bypass surgery and that the 10 year survival rate of these patients is the same as YEARS POSTOP. that for patient s treated for isolated valvular heart disease alone. In addition , coronary bypass surgery can be performed at a low risk, and coronary bypa ss surgery has alread y been demonstrated by pro specti ve randomized studies to prolon g life in some groups of patient s with coronary arter y disease (for example , those with left main coronary artery disease and three vessel coronary artery disease [23] ). Difficulties of performing a randomized study. Perhaps the only way to resolve this issue would be to perform a prospective randomized study . However, the difficulties of performing such a study need to be emphasized . The inciden ce of associated coronary artery disease in patient s with valvular heart disease who are being considered for valve surgery ranges from 24 to 35% (one vessel disease in 2 to 18%, two vessel disease in 10 to 13% and three vessel disease in 7 to 29%). In order to obtain definitive answers about coronary bypass surgery for isolated coronary artery disease more than 500 to 1000 randomized patients would be requi red . When one adds in variables of valvular heart disease . it is clear that one would require seve ral thousands of patients with valvular heart disease and associated co ronary artery disease to perform a success ful study . It must be rememb ered that this subgroup of patients con stitutes only approximately 25 to 35% of the total pool of patients with valvular heart disease: therefore , an enormous numb er of patient s will have to be screened in order to obtain several thousand patients who could be entered into such a prospective randomized study; the difficulties of performing such a study are ev ident.
Cardiac Catheterization and Angiography
Recently it has been debated whether patients who are undergoing valve replacement should (24, 50, 51) or should not (46, 47) have preoperative cardiac catheterization and angiography. Major arguments affirming the view that cardiac catheterization and angio graphy are necessary can be summarized: I) the logic of the experimental method of those who recommend card iac catheterization not be performed-namely, that of studyi ng the need for cardiac catheterization by an ev aluation of operative and late mortality and postoperative complications-is inappropriate: 2) previous exper ience in bypassing cardiac catheterization does not prove that it is right and co rrec t to do so: 3) the accur acy and reprodu cibility of the history and physical examination in diagnosing all valve lesion s and eva luating their severity both pre-and postoperatively are not known; 4 ) the history, physical examination, che st X-ray film and electrocardiogram are not reliable for evaluating left ventricular dysfunction; 5) M-mode echo cardiography is not reliable in evaluating the severity of all valve disease , evaluating left ventricular function or dete ctin g malfunction of mechanical prosthe ses; 6) the history , phy sical examination and noninvasive tests are not reliable in detecting the presence, extent and severity of associated coronary artery disease; 7)
the reliab ility of the surgeo n in detectin g and accurately evaluating the seve rity of all valve lesions is not known : 8) patient s with severe valve disease might be den ied surgery: and 9) patient s with mild or moderate valve disease may undergo unnecessary valve replacem ent , a potenti ally disastrou s complication in such patient s.
Echocardiograph y and Radionuclide Studies
Both of these techniques represent major advances in the diagno sis and evaluation of patients with valvular heart disease (24) . Radionuclide studies provide a reliable quantitation of left ventricular ejection fraction. They also permit calculation of the total amount of regurgitation present in the left or right heart valve s if patients have valve regurgitation in only one side of the heart (52) . Echocardiography has proved a reliable tool in the diagno sis of valvular lesion s; however , in most instances, it has not proved reliable for assessing the severity of valvular heart disease. It is extremel y helpful in the diagnose s of anatomic lesions that were not clinically suspected . M-mode echocardiography has not been reliable in the quantification , and at times in the detection , of left ventricular dysfunction . Initial data on use of two-dimensional echocardiograph y (53) are most encouraging and hold great promi se that it may be a much more reliabl e technique than M-mode echoca rdiog raphy in evaluating left ventricular function . Moreover, criteria developed from echoca rdiog raphy as indicators for the need for valve surgery have also proved unreliable (24) .
Commissurotomy for Mitral Stenosis
The modern era of surgery for acquired valvular heart disease began with this procedure . Commissurotomy for mitral stenosis has undergone many change s, and currently in the United States this procedure is usually performed under direct vision with the utilization of extracorporeal circu lation . The results in experienced hand s (54) are impressive: operative mortality rate is low « 1%). perioperative morbidity is small and the 10 year incidence of thromboembolism and death after successful mitral commissurotomy is 3 ± 2% (Fig. 13) . Most patients experience an improvement in the symptomatic state and in hemod ynami cs with reduct ion of left atrial and pulm onary artery pres sures and an impro vement in cardiac index (15-17 ,42) ; however, patients need reoperation at an incre asing rate , approximately 5 to 7 years after successful commissurotomy (54) . Mitral commissurotomy is the procedure of choice in patient s with isolated seve re mitral stenosis, but it usually is not suitable for those with a calcified and a rigid nonmobile valve .
Valve Replacement Versus Valve Repair for Mitral Regurgitation
Mitral valve repair can be success fully performed with experience in some patients with mitral regurgitation. Late survival (Fig. 14) , the incidence of thromboembolism , the symptomatic improvement and the return of hemod ynamics toward the normal range are most encouraging (55) . The best results are obtained in patient s with a myxomatous mitral valve (mitral valve prolapse syndrome); the results in patients with rheumati c mitral valve disease are discouraging and the results in patients with mitral regurgit ation secondary to coronary artery disease are less than ideal (55) .
Vasodilators
By reducing impedance to left ventricular ejection, arterial dilators favor increased output of blood from the left ventricie to the aorta and , thus, a reduction in mitral regurgitation and left atrial pressure (56, 57) . The same drugs, by reducing the arterial resistance , favo r the forward output of blood from the aorta to the periphery and , thus, result in a reduction of aorti c regurgitat ion (58, 59) . For these reasons, vasodilators have proved to be of great value in treating patients with valvular heart disease who have heart failure. particularly in the presence of acute valvular regurgitation (56) . Long-term treatm ent with arterial dilators in patients with mitral regurgitation has proved to provide less than ideal results (57); in 25% of patient s hydralazine had to be discontinued because of adver se effects, and in another 25 100% ... 10 Vears to 30% the drug produced hemodynamic improvement that was not translated into symptomatic improvement. Thus, in a short follow-up period of an average of 13 months, satisfactory results were obtained in less than half of the patients. In one patient with aortic regurgitation treated with long-term hydralazine therapy, a major reduction in left ventricular volume and mass and dramatic improvement in left ventricular ejection fraction and functional class were demonstrated (60) . The role of arterial dilators in the longterm treatment of patients with valvular heart disease is being further evaluated.
Infective Endocarditis
Early diagnosis and treatment of heart failure. The case fatality rate from infective endocarditis is 30 to 40% (61, 62) . Although this is a great improvement over the 95 to 100% mortality rate in the period before antiobiotic therapy, the mortality rate remains remarkably high. The major cause of death is congestive heart failure. which occurs in 60% of patients. In most instances. heart failure is due to severe aortic or mitral regurgitation, or both. Valve replacement alleviates the hemodynamic load of valve regurgitation; thus, valve surgery plays an important role in the care of patients with infective endocarditis. For both native valve and prosthetic valve endocarditis with heart failure. patients treated surgically have a lower hospital mortality rate than those treated nonsurgically (22) . These differences are greatest in patients with moderate and severe heart failure ( Table  7) . Therefore, if the high mortality rate of congestive heart failure is to be reduced, early, aggressive diagnosis and treatment of congestive heart failure are essential. The indications for valve surgery are listed in Table 8 .
Treatment regimen.
In patients with infective endocarditis who have moderate to severe congestive heart failure, admission to an acute cardiac care unit and hemodynamic monitoring with a balloon-flotation catheter are mandatory (62) . Appropriate antibiotic therapy should be started as soon as possible. Medical therapy for heart failure should then be promptly instituted with digoxin and diuretic drugs; vasodilators (arterial or venous dilators, or both) are also usually needed. Sodium nitroprusside. which is both an arterial and venous dilator. is the drug of choice in the acutely ill patient. After the congestive heart failure has been controlled with aggressive medical therapy, cardiac catheterization is almost invariably indicated to define the presence of all correctable lesions. and can be performed safely at low risk by experienced workers. Valve replacement or repair of any correctable lesions can then be performed on a nonemergent basis once the congestive heart failure is controlled, regardless of the duration of antibiotic therapy. When heart failure cannot be controlled, surgery should not be delayed if the patient has an operable lesion.
The clinical diagnosis and assessment of patients with infective endocarditis and mild congestive heart failure are often wrong. Therefore. these patients should also be admitted to an acute cardiac care unit for hemodynamic monitoring (62) . If congestive heart failure is present. medical therapy consisting of digoxin and diuretic drugs should be started. Vasodilators are often also needed in these patients. If the congestive heart failure is not easily controlled with medical therapy alone, valve replacement should be performed after cardiac catheterization. If the congestive heart failure is well controlled. medical therapy for the congestive heart failure and antibiotic drugs for the infection can be continued and the patients reassessed after 4 to 6 weeks.
It is to be emphasized that the clinical and hemodynamic spectrum ofpatients with infective endocarditis and congestive heart failure is a continuum; therefore, if one is unsure whether congestive heart failure is absent. it is mandatory to find out through hemodynamic monitoring because of the serious consequences of a clinical error. Clinical assessment of severity of congestive heart failure and its response to therapy is often misleading. Only after the severity of congestive heart failure is hemodynamically assessed can appropriate decisions be made regarding medical and surgical therapy.
Acute Valvular Regurgitation
A common cau se of acute valvular regurgitat ion is infect ive endocarditi s. Other causes include dissection of the aorta , traum a, myocardial infarction and idiopathic cau ses. Aorti c regurgit ation associated with dissection of the aorta is an indic ation for surgery . Patients who have cardiac traum a should be full y evaluated and a decision regarding surgery should be made on the basis of the findings (63) . In other patient s, the usual indication for valvular surgery is severe valvul ar regurgitation associated with symptoms or other problems such as left ventricular dysfunction.
Etiology of Heart Disease
The onset of better social and hygienic conditions in the first half of this century resulted in a dramatic reduction in the incidence of rheumatic fever (64 ) . A reduced incidence of rheumatic fever would be expected to result in a reduction in the inciden ce of rheum atic heart disease after several decades: this expectation has been fulfilled . Currently in the United States, there is a rem arkable reduction in the incidence of rheumatic heart disease and in the percent of patient s who undergo valve surgery becau se of rheumatic involvement of the heart . In large parts of the United States the most common indication for valve surgery is calcific aort ic valve stenosi s. Prolapse of the mitral valve is a common valve disease that first gained general clinical recognition in the late 1950s, as is mitral regurgitation resultin g from coro nary artery disease and severe left ventricular dysfunction. Val vular endocarditis is co mmon among intravenous drug abu sers. Rheumatic heart disea se cont inues to be seen at an increasing rate in those parts of the United States that have a significant popul ation of immigrants from underd eveloped parts of the world ; it also continues to be seen in patients who live in the inner cities .
Antibiotic Prophylaxis
Ant ibiotic prophylaxis is undert aken in patients with rheumatic and other form s of valvular heart disease for two purposes: I) prevent ion of recurrences of rheumatic fever: and 2) pre vention of infective endocarditis. In patient s who already have rheumatic heart disease , secondary prevention is the goa l, and several studies have documented the incre ased risk of further morbidity and mortality from streptococcal infection and the efficacy of antibioti c treatment. Alth ough the effectiveness of prophylaxis against infective endocarditi s has not been proved , a lack of effect has also not been proved . Moreover , infective endo cardit is is associa ted with a high mortality rate , the complications are often disastrous and, even after success ful treatment. permanent and serious sequelae may remain. How often infecti ve endocarditis has been prevented by antibiotic prophylaxis is completely unknown. Therefore, at the present time , antibiotic proph yla xis for the prevention of infect ive endoca rditis is essenti al on clinical grounds and should be agg ressively undertaken. The recommendations of the American Heart Association for the prevention of recurrences of rheumatic fever and for proph ylaxis again st infective endoc arditis repre sent the currently recognized standard of practice in the United States (65) (66) (67) .
